Compare Oracle Corporation (ORCL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Revvity Inc — how do they compare? Oracle Corporation trades at $127.1 (market cap $365.96B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Oracle Corporation is far larger — about 29.7× Revvity Inc's market cap, and Oracle Corporation pays the higher dividend (1.57%). Which is the better fit depends on your goals.
| ORCL | RVTY | |
|---|---|---|
Market Cap | $365.96B | $12.33B |
Sector | Technology | Technology |
52-Week High | $328.33 | $117.75 |
52-Week Low | $121.37 | $82.26 |
Enterprise Value | $495.21B | $14.82B |
Dividend Yield | 1.57% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) is trading at $121.37, down 4.04% today, reflecting recent market volatility. The stock shows strong fundamentals with consistent earnings beats (Q3 2025-Q1 2026) and robust profitability metrics including 65.82% gross margin and 58.56% ROE. Technical indicators are mixed with a bearish moving average signal but bullish RSI readings. Recent news highlights Oracle's AI infrastructure expansion and partnership with OpenAI, driving investor interest despite concerns about capital requirements.
Oracle presents a compelling investment case with strong analyst support (65% buy ratings) and a $253.30 consensus price target representing significant upside. Key opportunities include AI-driven growth and cloud expansion, while risks involve high debt levels ($92.6B total liabilities) and competitive pressures in enterprise software. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
